Overview
NICE is unable to make a recommendation on canagliflozin (Invokana) for treating type 2 diabetes mellitus in children and young people 10 to 17 years. This is because the company did not provide an evidence submission.
Last reviewed: 25 February 2026
Next review: We will review this decision if the company decides to make a submission.